Informations de base

Titre	Activase® (alteplase) for acute ischemic stroke treatment
Description	Acute ischemic stroke indication: activase is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (ct) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see contraindications in the full prescribing information). acute massive pulmonary embolism indication: activase is indicated in the management of acute massive pulmonary embolism (ampe) in adults: (1) for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lungs; (2) for the lysis of pulmonary emboli accompanied by unstable hemodynamics, eg, failure to maintain blood pressure without supportive measures. the diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning. acute mycocardial infarction indication: activase (alteplase) is indicated for use in the management of acute myocardial infarction in adults for the improvement of ventricular function following ami, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with ami. treatment should be initiated as soon as possible after the onset of ami symptoms. important safety information: contraindications acute ischemic stroke (ais): treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (ct) scan or other diagnostic imaging method sensitive for the presence of hemorrhage [see contraindications in the full prescribing information]. activase therapy in patients with ais is contraindicated in certain situations (eg, suspicion of subarachnoid hemorrhage on pretreatment evaluation), recent (within 3 months) intracranial or intraspinal surgery, history of intracranial hemorrhage, uncontrolled hypertension at time of treatment, active internal bleeding, known bleeding diathesis (eg, current use of oral anticoagulants, administration of heparin within 48 hours of onset of stroke, platelet count <100,000/mm3) [see contraindications in the full prescribing information]. pulmonary embolism (pe): activase therapy in patients with pe is contraindicated in certain situations (eg, active internal bleeding, history of cerebrovascular accident, recent intracranial or intraspinal surgery or trauma, severe uncontrolled hypertension) [see contraindications in the full prescribing information]. acute myococardial infarction (ami): activase therapy in patients with acute myocardial infarction (ami) is contraindicated in certain situations because of an increased risk of bleeding (e.g. active internal bleeding, history of cerebrovascular accident, recent intracranial or intraspinal surgery or trauma, severe uncontrolled hypertension) [see contraindications in the full prescribing information]. warnings the risks of activase therapy for all approved indications may be increased and should be weighed against the anticipated benefits in certain conditions [see warnings in the full prescribing information]. cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. acute ischemic stroke (ais): patients with severe neurological deficit (eg, nihss >22) at presentation. there is an increased risk of intracranial hemorrhage in these patients. patients with major early infarct signs on a computerized cranial tomography (ct) scan (eg, substantial edema, mass effect, or midline shift). treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended [see warnings in the full prescribing information]. pulmonary embolism (pe): treatment of pe with activase has not been shown to constitute adequate clinical treatment of underlying deep vein thrombosis. the possible risk of reembolization due to the lysis of underlying deep venous thrombi should be considered. acute myococardial infarction (ami): coronary thrombolysis may result in arrhythmias associated with reperfusion. it is recommended that antiarrhythmic therapy for bradycardia and/or ventricular irritability be available when infusions of activase are administered. precautions (ais) orolingual angioedema has been observed in postmarketing experience in patients treated with activase for ais. patients should be monitored during and for several hours after infusion for signs of orolingual angioedema. adverse reactions the most common complication during activase therapy is bleeding. should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, activase therapy should be discontinued immediately, along with any concomitant therapy with heparin. death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes. please see www.activase.com for full prescribing information for additional important safety information. activase® (alteplase) is the only fda-approved drug for the treatment of acute ischemic stroke.
Analytics ID	UA-6467920
Adsense ID	/
Adresse IP	72.34.128.168

Trafic

Chaque jour, activase.com génère 44 535 pages vues pour 8 907 visiteurs. Le site enregistre en moyenne 276 117 visites et 1 380 585 pages vues par mois. Une note de C lui est attribuée en raison de ses bonnes performances.

	Par jour	Par semaine	Par mois	Par an
Visiteurs	8 907	62 349	276 117	3 251 055
Pages vues	44 535	311 745	1 380 585	16 255 275

Potentiel SEO

Activase.com possède un Pagerank Google de 4 sur 10 et un Rank Alexa de 76 815. Bien qu'étant de plus en plus déprécié en tant qu'indicateur de la qualité d'un site web, un PageRank élevé continue néanmoins d'indiquer dans la plupart des cas la popularité d'un site web. Les sites ayant un Rank Alexa élevé ont un nombre important de visiteurs, indiquant ainsi un positionnement performant dans les résultats des moteurs de recherche.

Le nom de domaine a été crée il y a 25 ans (année : 1999, mois : 04, jour : 23) et sa longueur est de 8 caractères. Les algorithmes des moteurs de recherche accordent plus de crédibilité et d'autorité aux sites web dont le nom de domaine a été enregistré depuis longtemps et continue d'être en activité (et non parqué).

Une note de C lui est attribuée en raison de ses bonnes performances.

Pagerank	4/10
Alexa	#76 815
Age	25 ans, 2 mois et 8 jours
Indexation	View pages indexed in : [Google] [Yahoo] [Bing]

Revenus

Activase.com génère 20 euros de revenus publicitaires par jour. Les revenus provenant des bannières au CPC sont de 7 391 euros par an. Les revenus annuels des bannières au CPM s'elèvent à 1 219 euros. Si le site était à vendre, il pourrait être vendu pour 54 859 euros. Une note de D lui est attribuée en raison de ses faibles performances.

	Par jour	Par semaine	Par mois	Par an
CPC	20	142	628	7 391
CPM	3	23	104	1 219

Information sur le serveur

Activase.com a pour adresse ip 72.34.128.168 et est hébergé à San Jose, États-Unis. La quantité de bande passante utilisée par Activase est de 3,733 Go par jour. Nous estimons ainsi que activase.com utilise un total de 1 serveur(s), avec un coût de 30 euros par mois.

Analyse de l'hébergement

Nombre de serveurs	1
Coûts des serveurs /mois	30
Bande passante /jour	3,733 Go

Localisation du serveur

Latitude	37.3394
Longitude	-121.895
Ville	San Jose
Pays	États-Unis

Emplacement du serveur de Activase : San Jose, États-Unis (37.3394,-121.895)

Domaines sur la même IP (72.34.128.168)

N°	Nom de domaine	Visiteurs
1.	activase.com (Activase)	8 907
2.	activase.us (Activase)	0